J. Goldman & Co’s Global Blood Therapeutics, Inc. GBT Stock Holding History

J. Goldman & Co’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-26,780	Closed	-$856K	–	534
2022 Q2	$856K	Sell	26,780 -87,312	-77%	-$2.56M	0.04%	257
2022 Q1	$3.95M	Buy	+114,092	New	+$3.41M	0.18%	140
2019 Q2	–	Sell	-33,789	Closed	-$1.79M	–	366
2019 Q1	$1.79M	Sell	33,789 -55	-0.2%	-$2.7K	0.1%	173
2018 Q4	$1.39M	Buy	+33,844	New	+$1.27M	0.11%	166
2018 Q2	–	Sell	-17,500	Closed	-$845K	–	486
2018 Q1	$845K	Buy	+17,500	New	+$976K	0.04%	270
2017 Q3	–	Sell	-58,600	Closed	-$1.6M	–	432
2017 Q2	$1.6M	Buy	+58,600	New	+$1.74M	0.09%	197
2016 Q3	–	Sell	-62,100	Closed	-$1.03M	–	438
2016 Q2	$1.03M	Buy	+62,100	New	+$1.25M	0.05%	255

Other funds holding GBT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

J. Goldman & Co's GBT Position: Q3 2022 in Review

J. Goldman & Co sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2022, closing a stake of 26,780 shares — an estimated $856K sold.

J. Goldman & Co first reported a position in GBT in Q2 2016 and held it in 7 quarters. The position peaked at $3.95M in Q1 2022. 247 funds tracked by Wall St. Rank hold GBT as of Q3 2022.

J. Goldman & Co reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2022 after selling out during the quarter.
J. Goldman & Co sold 26,780 Global Blood Therapeutics, Inc. shares in Q3 2022, an estimated $856K.
J. Goldman & Co first reported a position in Global Blood Therapeutics, Inc. in Q2 2016 and held it in 7 quarters.
J. Goldman & Co's Global Blood Therapeutics, Inc. position peaked at $3.95M in Q1 2022.
247 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2022.

Based on J. Goldman & Co's 13F filing for Q3 2022, filed 14 Nov 2022.